Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease
| Autor: | Katarzyna Stankowska, Grażyna Gadomska, Danuta Rość, Radosław Wieczór, Barbara Ruszkowska-Ciastek, Jacek Fabisiak, Grzegorz Pulkowski, Jacek Budzyński, Karol Suppan |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty Angiogenesis Type 2 diabetes General Biochemistry Genetics and Molecular Biology Peripheral Arterial Disease chemistry.chemical_compound Diabetes mellitus Internal medicine medicine Humans General Pharmacology Toxicology and Pharmaceutics Aged Vascular Endothelial Growth Factor Receptor-1 General Veterinary business.industry Type 2 Diabetes Mellitus Articles General Medicine Middle Aged medicine.disease Vascular Endothelial Growth Factor Receptor-2 Vascular endothelial growth factor B Vascular endothelial growth factor Vascular endothelial growth factor A Endocrinology Diabetes Mellitus Type 2 Vascular endothelial growth factor C chemistry Female business Diabetic Angiopathies |
| Zdroj: | Journal of Zhejiang University-SCIENCE B. 16:948-956 |
| ISSN: | 1862-1783 1673-1581 |
| Popis: | Objective: Type 2 diabetes coexistent with lower extremity artery disease (peripheral arterial disease (PAD)) can be observed in numerous patients. The mechanism compensating for ischemia and contributing to healing is angiogenesis—the process of forming new blood vessels. The purpose of this study was to assess the likely impact of type 2 diabetes on the plasma levels of proangiogenic factor (vascular endothelial growth factor A (VEGF-A)) and angiogenesis inhibitors (soluble VEGF receptors type 1 and type 2 (sVEGFR-1 and sVEGFR-2)) in patients with PAD. Methods: Among 46 patients with PAD under pharmacological therapy (non-invasive), we identified, based on medical history, a subgroup with coexistent type 2 diabetes (PAD-DM2+, n=15) and without diabetes (PAD-DM2−, n=31). The control group consisted of 30 healthy subjects. Plasma levels of VEGF-A, sVEGFR-1, and sVEGFR-2 were measured using the enzyme-linked immunosorbent assay (ELISA) method. Results: The subgroups of PAD-DM2+ and PAD-DM2− revealed significantly higher concentrations of VEGF-A (P=0.000 007 and P=0.000 000 1, respectively) and significantly lower sVEGFR-2 levels (P=0.02 and P=0.000 01, respectively), when compared with the control group. Patients with PAD and coexistent diabetes tended to have a lower level of VEGF-A and higher levels of sVEGFR-1 and sVEGFR-2 comparable with non-diabetic patients. Conclusions: The coexistence of type 2 diabetes and PAD is demonstrated by a tendency to a lower plasma level of proangiogenic factor (VEGF-A) and higher levels of angiogenesis inhibitors (sVEGFR-1 and sVEGFR-2) at the same time. Regardless of the coexistence of type 2 diabetes, hypoxia appears to be a crucial factor stimulating the processes of angiogenesis in PAD patients comparable with healthy individuals, whereas hyperglycemia may have a negative impact on angiogenesis in lower limbs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink